About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker ACRS · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 13, 2026Study of Modzatinib (ATI-2138) in Adult Participants With Biopsy-proven Forms of Lichen Planus Not…
NCT07935590 · Lichen Planus
Modzatinib, Placebo
ACRS
Aclaris Therapeutics, Inc.
Phase 2Not yet recruiting102Mar 2029Registry ↗
Sep 29, 2026ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
NCT07011706 · Atopic Dermatitis, Atopic
ATI-045, Placebo
ACRS
Aclaris Therapeutics, Inc.
Phase 2Active, not recruiting110Sep 21, 2026Registry ↗
Sep 28, 2026ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Act…
NCT05279417 · Rheumatoid Arthritis
ATI-450 50 mg oral tablet BID, Placebo oral tablet
ACRS
Aclaris Therapeutics, Inc.
Phase 2Completed251Sep 5, 2023Registry ↗
Mar 12, 2026Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT06585202 · Atopic Dermatitis
ATI-2138
ACRS
Aclaris Therapeutics, Inc.
Phase 2Completed14Mar 13, 2025Registry ↗
Jan 7, 2026ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
NCT05216224 · Hidradenitis Suppurativa
ATI-450, Placebo oral tablet
ACRS
Aclaris Therapeutics, Inc.
Phase 2Completed95Dec 23, 2022Registry ↗
Nov 27, 2024Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis
NCT05511519 · Psoriatic Arthritis
ATI-450, Placebo Oral Tablet
ACRS
Aclaris Therapeutics, Inc.
Phase 2Terminated47Dec 6, 2023Registry ↗
Oct 26, 2024Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis
NCT05432596 · Atopic Dermatitis
ATI-1777 2.0% w/w, ATI-1777 1.0% w/w
ACRS
Aclaris Therapeutics, Inc.
Phase 2Completed250Oct 26, 2023Registry ↗
Sep 28, 2023Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis
NCT04598269 · Atopic Dermatitis
ATI-1777, Vehicle
ACRS
Aclaris Therapeutics, Inc.
Phase 2Completed50Apr 8, 2021Registry ↗
Sep 21, 2023Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)
NCT04524858 · Cryopyrin-Associated Periodic Syndrome
ATI-450
ACRS
Aclaris Therapeutics, Inc.
Phase 2Terminated1Feb 25, 2021Registry ↗
Mar 29, 2023Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA
NCT04247815 · Rheumatoid Arthritis
ATI-450, Placebo oral tablet
ACRS
Aclaris Therapeutics, Inc.
Phase 2Completed25Feb 4, 2021Registry ↗
Dec 9, 2020A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solut…
NCT03495817 · Androgenetic Alopecia
ATI-50002
ACRS
Aclaris Therapeutics, Inc.
Phase 2Completed31Oct 15, 2019Registry ↗
Dec 2, 2020Study of A-101 for the Treatment of Seborrheic Keratosis
NCT02260180 · Seborrheic Keratosis
A-101
ACRS
Aclaris Therapeutics, Inc.
Phase 2Completed119Mar 2015Registry ↗
Nov 30, 2020A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo
NCT03468855 · Vitiligo
ATI-50002 topical solution
ACRS
Aclaris Therapeutics, Inc.
Phase 2Completed34Oct 16, 2019Registry ↗
Nov 23, 2020Safety Study of A-101 Topical Solution for the Treatment of Common Warts
NCT03812510 · Common Wart
A-101
ACRS
Aclaris Therapeutics, Inc.
Phase 3Completed426Nov 27, 2019Registry ↗
Oct 27, 2020A Study of A-101 Topical Solution for the Treatment of Common Warts
NCT03691831 · Common Wart
Active, Vehicle
ACRS
Aclaris Therapeutics, Inc.
Phase 3Completed502Apr 21, 2019Registry ↗
Oct 6, 2020ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and A…
NCT03759340 · Alopecia Areata, Alopecia Universalis
ATI 502 0.46% Topical Solution
ACRS
Aclaris Therapeutics, Inc.
Phase 2Terminated56Sep 11, 2019Registry ↗
Oct 5, 2020Study of A-101 Topical Solution for the Treatment of Common Warts
NCT03687372 · Common Wart
A-101, vehicle
ACRS
Aclaris Therapeutics, Inc.
Phase 3Completed503Jun 20, 2019Registry ↗
Sep 16, 2020ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis…
NCT03594227 · Alopecia
ATI-501 400mg BID (Low dose), ATI-501 600mg BID (Mid dose)
ACRS
Aclaris Therapeutics, Inc.
Phase 2Completed87Jun 6, 2019Registry ↗
Jul 2, 2020Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopec…
NCT03315689 · Alopecia Universalis (AU), Alopecia Totalis (AT)
Vehicle, ATI-50002
ACRS
Aclaris Therapeutics, Inc.
Phase 2Completed11Jun 20, 2019Registry ↗
Jun 5, 2020A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
NCT03354637 · Alopecia Areata
ATI-50002 high dose, ATI-50002 low dose
ACRS
Aclaris Therapeutics, Inc.
Phase 2Terminated129Apr 18, 2019Registry ↗
Mar 30, 2020A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra
NCT03224598 · Dermatosis Papulosa Nigra
A-101 Topical Solution 40%
ACRS
Aclaris Therapeutics, Inc.
Phase 2Completed39Jan 8, 2019Registry ↗
Feb 17, 2020A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis
NCT03585296 · Atopic Dermatitis
ATI-502
ACRS
Aclaris Therapeutics, Inc.
Phase 2Completed22Apr 25, 2019Registry ↗
Dec 11, 2019Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due…
NCT03551821 · Alopecia Areata, Alopecia Totalis
ATI-50002
ACRS
Aclaris Therapeutics, Inc.
Phase 2Completed1Nov 6, 2018Registry ↗
Oct 2, 2019An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses
NCT03487588 · Seborrheic Keratosis
A-101 Topical Solution
ACRS
Aclaris Therapeutics, Inc.
Phase 4Completed41Nov 14, 2018Registry ↗
Sep 4, 2019Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With Rosacea
NCT03380390 · Rosacea
Oxymetazoline HCL 1.0% Cream, Energy-Based Therapy
ACRS
Aclaris Therapeutics, Inc.
Phase 4Completed46Jun 15, 2018Registry ↗
May 6, 2019A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic…
NCT03148691 · Seborrheic Keratosis
A-101
ACRS
Aclaris Therapeutics, Inc.
Phase 2Completed253Feb 28, 2018Registry ↗
May 1, 2019A Phase2 of A-101 Topical Solution in Subjects With Common Warts
NCT03210337 · Common Wart
A-101 Topical Solution, A-101 Vehicle Solution
ACRS
Aclaris Therapeutics, Inc.
Phase 2Completed157Mar 16, 2018Registry ↗
Apr 9, 2019A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts
NCT03278028 · Common Wart
A-101 Topical Solution, A-101 Vehicle Solution
ACRS
Aclaris Therapeutics, Inc.
Phase 2Completed159Mar 1, 2018Registry ↗
Jan 3, 2019Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis
NCT02160626 · Seborrheic Keratosis
A-101 Vehicle, A-101 (40) Topical Solution
ACRS
Aclaris Therapeutics, Inc.
Phase 2Completed172Dec 2014Registry ↗
Dec 11, 2018Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis
NCT01986920 · Seborrheic Keratosis (SK)
A-101 25%, A-101 32.5%
ACRS
Aclaris Therapeutics, Inc.
Phase 1/2Completed35Feb 25, 2014Registry ↗
Dec 7, 2018A Study of A-101 Solution in Subjects With Common Warts.
NCT02669862 · Common Warts
A-101 Solution 40, A-101 Solution 45
ACRS
Aclaris Therapeutics, Inc.
Phase 2Completed98Sep 16, 2016Registry ↗
Feb 7, 2018An Open-Label Safety Study of A-101 Solution
NCT02667288 · Seborrheic Keratosis
A-101 Solution
ACRS
Aclaris Therapeutics, Inc.
Phase 3Completed147Oct 2016Registry ↗
Feb 6, 2018A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis
NCT02667275 · Seborrheic Keratosis
A-101 Solution, Vehicle Solution
ACRS
Aclaris Therapeutics, Inc.
Phase 3Completed487Oct 2016Registry ↗
Feb 6, 2018A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.
NCT02667236 · Seborrheic Keratosis
A-101 Solution, Vehicle Solution
ACRS
Aclaris Therapeutics, Inc.
Phase 3Completed450Oct 2016Registry ↗

34 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:10 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances